Prestige Consumer Healthcare Inc. (PBH) stock price, news, quote and history
This article provides a comprehensive financial overview of Prestige Consumer Healthcare Inc. (PBH), including its stock price, historical data, key statistics, and analyst insights. The company, which manufactures and markets OTC health and personal care products, saw its stock close at $55.13, up 5.05%, with a year-to-date return of 10.63%. The report also details the company's segments, product brands, and recent financial performance.
PBH Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an analysis of Prestige Consumer Healthcare Inc (PBH)'s financial performance, focusing on its revenue breakdown, profitability margins, and competitive positioning. The company's largest revenue contributor is North American OTC Healthcare-Women's Health, and it maintains strong gross, operating, and net margins. A comparison with competitors VRDN and TARS highlights PBH's efficiency within the Pharmaceuticals industry.
Prestige Consumer Healthcare Inc (PBH) Trading Down 6.76% on Apr 2
Prestige Consumer Healthcare Inc (PBH) shares dropped 6.76% on April 2nd, trading at $53.78, which is 39.82% below its 52-week high. Wall Street analysts maintain an "Outperform" rating, with an average target price of $78.20, suggesting a 45.41% upside. GuruFocus estimates the fair value at $70.94, indicating a 31.91% upside.
Prestige Consumer Healthcare stock hits 52-week low at 56.86 USD
Prestige Consumer Healthcare (PBH) stock recently reached a 52-week low at $56.86, marking a 33% decline over the past year, despite being considered undervalued relative to its Fair Value by InvestingPro data. The company reported stable third-quarter 2026 earnings, meeting analyst expectations, and announced a significant acquisition of the Breathe Right brand and other brands from Foundation Consumer Healthcare for approximately $900 million net. Management's aggressive share buyback program signals confidence in the company's future amidst these developments.
Allspring Global Investments Holdings LLC Acquires 21,085 Shares of Prestige Consumer Healthcare Inc. $PBH
Allspring Global Investments Holdings LLC increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1.3%, acquiring an additional 21,085 shares to hold a total of 1,613,460 shares, valued at approximately $98.78 million. Despite this institutional accumulation, Prestige Consumer Healthcare recently missed quarterly earnings estimates and provided FY2026 guidance, leading analysts to maintain a "Hold" rating with an average target price of $76.50. Institutional ownership of the stock remains high at 99.95%, although a company VP recently sold 1,000 shares.
The Technical Signals Behind (PBH) That Institutions Follow
The article details technical signals for Prestige Consumer Healthcare Inc. (NYSE: PBH), indicating a weak sentiment across all horizons which supports a short bias. It outlines distinct AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis highlights an exceptional risk-reward setup targeting a 12.2% gain against a 0.3% risk.
PBH Technical Analysis & Stock Price Forecast
The technical analysis for Prestige Consumer Healthcare Inc. (PBH) indicates a "Strong Sell" consensus, based on an aggregation of 14 technical signals as of March 27, 2026. The stock is currently trading below its 60-day and 200-day moving averages, with key support at $58.47 and resistance at $64.055. Momentum indicators like MACD also suggest a sell signal, while RSI is in neutral territory.
Vanguard (PBH) amendment shows 0 shares; reporting split after Jan 12, 2026
The Vanguard Group filed Amendment No. 17 to its Schedule 13G/A for Prestige Consumer Healthcare Inc. (PBH), reporting 0 shares beneficially owned and 0% of Common Stock. This change is due to an internal realignment effective January 12, 2026, which led to disaggregated reporting by Vanguard subsidiaries. The amendment was signed by Ashley Grim on March 27, 2026.
Congress Asset Management Co. Has $20.91 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH
Congress Asset Management Co. significantly increased its stake in Prestige Consumer Healthcare Inc. by 14.8% during the fourth quarter, now holding 339,018 shares valued at $20.91 million. This makes them owners of approximately 0.71% of the company, which is largely institutionally owned (99.95%). Despite this, Prestige Consumer Healthcare recently missed quarterly earnings estimates, reporting $1.14 EPS against an expected $1.16, and revenue of $283.44 million versus $286.93 million, with revenue down 2.4% year-over-year.
Prestige Consumer to acquire Breathe Right brand in $1.05 billion deal
Prestige Consumer Healthcare is set to acquire the Breathe Right brand from Foundation Consumer Healthcare for approximately $1.045 billion, marking its entry into the nasal strip market. The acquisition is expected to boost Prestige's core profit and will make Breathe Right the largest brand in its portfolio, aligning with the company's strategy of acquiring strong, cash-generating OTC brands. The deal is projected to close in the first half of 2027.
Prestige Consumer Healthcare to buy Breathe Right, other brands for $1.045 billion
Prestige Consumer Healthcare announced its acquisition of Breathe Right and other over-the-counter brands from GSK for $1.045 billion. This strategic move aims to expand Prestige's portfolio with established brands, leveraging its existing infrastructure for growth and shareholder value. The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals.
Prestige Consumer Healthcare to buy Breathe Right, other brands for $1.045 billion
Prestige Consumer Healthcare plans to acquire the Breathe Right, Fiber Choice, and SlowMag brands from GlaxoSmithKline and Sanofi for a total of $1.045 billion. This acquisition is expected to be immediately accretive to Prestige's adjusted earnings per share and free cash flow per share, highlighting a strategic move to expand its consumer healthcare portfolio.
Nordea Investment Management AB Has $37.81 Million Holdings in Prestige Consumer Healthcare Inc. $PBH
Nordea Investment Management AB significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by 547.4% in the fourth quarter, now holding 615,215 shares valued at $37.81 million. Despite this increased institutional interest, Prestige Consumer Healthcare recently missed quarterly earnings and revenue estimates and holds a consensus "Hold" rating from analysts with an average target price of $76.50. Company VP Jeffrey Zerillo also sold 1,000 shares of the company's stock, reducing his direct ownership.
Prestige Consumer Healthcare: Accretive Breathe Right Acquisition Reinforces Buy Rating and $86 Target
Canaccord Genuity analyst Susan Anderson has reiterated a Buy rating and an $86 price target for Prestige Consumer Healthcare (PBH). The positive outlook follows PBH's $1.045 billion acquisition of Breathe Right and other OTC brands, which is expected to significantly boost sales (18%) and EPS. Anderson notes that the acquisition aligns with PBH's strategy of targeting high-margin, growing brands and is financed within a manageable leverage range.
Prestige Consumer Health to acquire Breathe Right for $1.045B
Prestige Consumer Health is set to acquire Breathe Right for $1.045 billion. This strategic acquisition aims to expand Prestige Consumer Health's portfolio within the respiratory health sector, leveraging Breathe Right's established brand presence. The deal underscores the company's commitment to growth through targeted brand acquisitions.
Precision Trading with Prestige Consumer Healthcare Inc. (PBH) Risk Zones
This article provides an AI-driven analysis of Prestige Consumer Healthcare Inc. (PBH), highlighting weak sentiment across all horizons and an exceptional 41.0:1 risk-reward setup. It outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for different risk profiles, along with multi-timeframe signal analysis and current support/resistance levels. The analysis aims to help traders optimize position sizing and minimize drawdown risk.
Prestige Consumer Healthcare to Buy Breathe Right, Other Brands for $1.045 Billion
Prestige Consumer Healthcare has agreed to acquire a portfolio of brands, including Breathe Right nasal strips and Dimetapp, from Foundation Consumer Healthcare for $1.045 billion. The acquired brands generated approximately $200 million in revenue in 2025. This deal was announced on Friday by Prestige.
Prestige Consumer Healthcare To Acquire Breathe Right
Prestige Consumer Healthcare Inc. is set to acquire the Breathe Right brand and other brands, including Dimetapp, from Foundation Consumer Healthcare for $1.045 billion. This acquisition is expected to enhance Prestige's portfolio with a leading nasal strip brand, contribute significantly to revenue and EBITDA, and be immediately accretive to the company's financial margins. The deal reinforces Prestige's long-term organic sales growth target and has a clear path to reducing net leverage.
Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips
Prestige Consumer Healthcare Inc. has announced an agreement to acquire Breathe Right® and other brands from Foundation Consumer Healthcare for $1.045 billion. The acquisition, which includes iconic brands like Breathe Right®, Dimetapp®, and Anbesol®, is expected to significantly boost Prestige's revenue and EBITDA, reinforcing its long-term growth strategy. This move expands Prestige’s portfolio into the attractive sleep and better-breathing categories and is anticipated to be accretive to margins and EPS, with a goal of rapid deleveraging.
Prestige Consumer Healthcare to Acquire Breathe Right and Other OTC Brands for $1.045 Billion
Prestige Consumer Healthcare has agreed to acquire a portfolio of over-the-counter consumer health products, including Breathe Right, from Foundation Consumer Brands for $1.045 billion in cash. This strategic acquisition is expected to expand Prestige's OTC portfolio and drive growth, with the closing anticipated in the first half of Fiscal 2027. The deal involves an asset purchase agreement and is subject to customary conditions and HSR clearance.
Prestige Consumer to Buy Breathe Right for $1.045B | PBH Stock News
Prestige Consumer Healthcare (NYSE: PBH) has announced an agreement to acquire Breathe Right and other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits. The acquired portfolio, which includes the iconic Breathe Right nasal strips and other established brands like Dimetapp, generated about $200 million in revenue and $95 million in EBITDA for the twelve months ending December 31, 2025. This acquisition is expected to be immediately accretive to Prestige's gross and EBITDA margins and EPS, and will be financed with cash on hand and a new term loan credit facility.
Prestige Consumer to buy Breathe Right brand in $1.05 billion deal
Prestige Consumer Healthcare announced its acquisition of the Breathe Right brand and other assets from Foundation Consumer Healthcare for $1.045 billion. This deal marks an expansion for Prestige into a new category, with Breathe Right expected to become the largest brand in its portfolio. The acquisition is projected to close in the first half of 2027 and be accretive to Prestige's core profit.
Prestige Consumer Healthcare Inc. Announces Agreement to Acquire Breathe Right Brand Portfolio for $1.045 Billion
Prestige Consumer Healthcare Inc. has announced an agreement to acquire the Breathe Right brand portfolio from Foundation Consumer Healthcare for $1.045 billion, with a net cost of approximately $900 million after tax benefits. This acquisition is expected to significantly enhance Prestige's brand portfolio, particularly in the sleep and better-breathing markets, and is projected to be accretive to gross and EBITDA margins. The transaction, which includes other established brands like Dimetapp and Anbesol, is anticipated to close in the first half of fiscal 2027.
Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips
Prestige Consumer Healthcare Inc. has announced an agreement to acquire the Breathe Right® brand and other associated brands from Foundation Consumer Healthcare for $1.045 billion. This acquisition will expand Prestige's portfolio into the nasal strip category with an established, iconic brand, complementing their long-term organic growth strategy. The deal is expected to contribute approximately $200 million in revenue and $95 million in EBITDA, resulting in immediate accretion to margins and EPS, with closing anticipated in the first half of fiscal 2027.
Breathe Right deal: Prestige (NYSE: PBH) plans $1.045B brand acquisition
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced its subsidiary Prestige Brands, Inc. will acquire the Breathe Right nasal strip brand and other over-the-counter consumer health brands from Foundation Consumer Healthcare for $1.045 billion in cash. This acquisition, expected to close in the first half of fiscal 2027, is anticipated to be margin-accretive, increase free cash flow, and support faster balance-sheet deleveraging, with the company aiming to return to its long-term leverage target by fiscal 2028. The deal adds a leading nasal strip brand and Dimetapp children's cough and cold relief to Prestige's portfolio, enhancing its scale and financial profile.
Clear Eyes supply disruption weighs on Prestige Consumer Healthcare Inc. (PBH)’s quarterly revenue
The article discusses the impact of a Clear Eyes supply disruption on Prestige Consumer Healthcare Inc. (PBH)'s quarterly revenue. It highlights how issues in product availability can negatively affect financial performance for consumer healthcare companies.
Clear Eyes supply disruption weighs on Prestige Consumer Healthcare Inc. (PBH)’s quarterly revenue
Prestige Consumer Healthcare Inc. (PBH) reported a supply disruption for its Clear Eyes product line, which is expected to negatively impact the company's quarterly revenue. This issue highlights potential vulnerabilities in the supply chain for consumer healthcare products and suggests a need for diversified sourcing or improved inventory management strategies. The disruption could affect investor perception and financial projections for the company in the short term.
How Prestige’s Media Agency Shift At Prestige Consumer Healthcare (PBH) Has Changed Its Investment Story
Prestige Consumer Healthcare recently appointed Horizon Media to handle its media planning and buying, aiming to improve brand reach and marketing efficiency through data-driven strategies. While this move supports new product launches like TheraTears, it doesn't fundamentally alter the existing investment narrative which centers on restoring growth and managing risks associated with concentration in a few mature over-the-counter brands. The company's future performance hinges on how effectively enhanced marketing translates into sustained business results and whether new product introductions can mitigate reliance on older brands.
How Prestige’s Media Agency Shift At Prestige Consumer Healthcare (PBH) Has Changed Its Investment Story
Prestige Consumer Healthcare recently appointed Horizon Media as its new media planning and buying agency to enhance brand reach and marketing efficiency. This move is expected to support new product launches like TheraTears, but the core investment narrative remains largely unchanged, with risks tied to brand concentration. Investors should consider the potential impact on revenue resilience and business performance.
Prestige Consumer Healthcare Selects Horizon Media as Agency of Record
Prestige Consumer Healthcare has appointed Horizon Media as its media planning and buying agency after a four-month competitive review. This partnership aims to leverage Horizon's data-driven insights and brand strategy expertise to enhance Prestige's market leadership and drive measurable business growth for its diverse portfolio of over-the-counter healthcare and wellness products. Both companies expressed enthusiasm for the collaboration, emphasizing effective consumer engagement, integrated digital strategies, and increased brand equity.
Capital Research Global Investors Sells 25,838 Shares of Prestige Consumer Healthcare Inc. $PBH
Capital Research Global Investors reduced its stake in Prestige Consumer Healthcare Inc. by 8.7% during the third quarter, selling 25,838 shares. While analysts maintain a "Hold" rating with an average target price of $80.60, Prestige recently missed quarterly EPS expectations and saw a 2.4% year-over-year revenue decline. The company has set its FY2026 guidance at 4.54 EPS.
Dimensional Fund Advisors LP Purchases 119,459 Shares of Prestige Consumer Healthcare Inc. $PBH
Dimensional Fund Advisors LP increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.8% in the third quarter, acquiring an additional 119,459 shares, bringing its total ownership to 5.39% valued at approximately $161.7 million. This increase occurred despite the company missing Q3 earnings estimates with EPS of $1.14 and a 2.4% year-over-year revenue decline. Analysts currently have a "Hold" consensus rating on PBH with a target price of $80.60, while the stock recently traded near $66.26.
Technical Reactions to PBH Trends in Macro Strategies
This article provides a technical analysis of Prestige Consumer Healthcare Inc. (NYSE: PBH), noting near-term weak sentiment and elevated downside risk. It outlines institutional trading strategies including long, breakout, and short positions with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data for support and resistance levels.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Recommendation of "Hold" by Brokerages
Prestige Consumer Healthcare Inc. (NYSE:PBH) has received an average "Hold" rating from seven analysts, with four rating it a hold and three a buy, and an average 1-year target price of $80.60. The company recently missed its quarterly earnings estimate with an EPS of $1.14 against an expected $1.16, and revenue was down 2.4% year-over-year at $283.4 million. Despite the earnings miss, the company has set its FY2026 EPS guidance at $4.540, which is close to analyst expectations.
PBH Earning Date, Earning Analysis and Earning Prediction
The article provides an in-depth analysis of Prestige Consumer Healthcare Inc. (PBH) earnings, including past performance, future predictions, and stock price reactions. It highlights the company's recent revenues and EPS, alongside analyst forecasts for Q4 2026, and discusses the correlation between earnings forecast revisions and stock price movements. Investors are given insights into potential buying opportunities and expected stock behavior around earnings reports.
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Analyst Consensus and 12% Upside Potential
Prestige Consumer Healthcare Inc. (PBH), a key player in the healthcare sector, is analyzed for its stock potential. Despite a slight revenue dip, the company maintains strong earnings and a favorable forward P/E ratio, with analysts projecting a 12.31% upside, signaling optimism for investors. Its diverse brand portfolio and strategic focus position it for future growth in the evolving healthcare landscape.
Assessing Prestige Consumer Healthcare (PBH) Valuation After Mixed Returns And An 11% Intrinsic Value Discount
Prestige Consumer Healthcare (PBH) has shown mixed recent share performance, with short-term gains but longer-term declines over the past year. The company's intrinsic value is estimated at $77.83, suggesting it is currently undervalued by 11% compared to its trading price of $69.30, primarily due to strong cash flow generation and improving gross margins. This narrative is supported by expectations of steady revenue, firmer margins, and a richer earnings multiple, though potential risks exist from supply chain issues or weaker e-commerce pricing.
JPMorgan Chase & Co. Grows Stock Holdings in Prestige Consumer Healthcare Inc. $PBH
JPMorgan Chase & Co. increased its stake in Prestige Consumer Healthcare Inc. by 30.1% in Q3, now holding 459,228 shares valued at approximately $28.7 million. Despite the increased institutional ownership, Prestige Consumer Healthcare slightly missed its Q3 earnings and revenue estimates. Analysts currently have an average "Hold" rating on the stock with a target price of $80.60, while recent Zacks updates show mixed estimate revisions.
Vanguard Group Inc. Lowers Position in Prestige Consumer Healthcare Inc. $PBH
Vanguard Group Inc. reduced its stake in Prestige Consumer Healthcare Inc. ($PBH) by 2.5% in the third quarter of 2025, selling over 140,000 shares but still owning a significant portion of the company. Despite institutional investors holding nearly all of the stock, the company recently missed Q4 earnings estimates, and analysts have a "Hold" rating with a mixed outlook, adjusting some forecasts downwards while other institutions show positive sentiment.
What is Zacks Research's Estimate for PBH Q1 Earnings?
Zacks Research has lowered its Q1 2027 EPS estimate for Prestige Consumer Healthcare (NYSE:PBH) to $1.09 per share from $1.24, while maintaining a "Hold" rating on the stock. The firm also adjusted its full-year EPS forecasts for 2027 and 2028 downwards. Despite certain institutional buying interests, the overall sentiment is weakening due to these downward revisions in near-term earnings expectations.
Trading the Move, Not the Narrative: (PBH) Edition
This article provides an AI-driven analysis of Prestige Consumer Healthcare Inc. (PBH), highlighting strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It outlines distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various horizons. The report emphasizes real-time signals, risk management, and personalized alerts available through Stock Traders Daily's platform.
Prestige Consumer Healthcare Inc. $PBH Stake Lifted by Heartland Advisors Inc.
Heartland Advisors Inc. significantly increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 41.4% in the third quarter, bringing its total holdings to 64,376 shares valued at approximately $4.02 million. This increase occurred despite recent insider selling by VP Jeffrey Zerillo and the company slightly missing its quarterly earnings estimates with $1.14 EPS against an expected $1.16, alongside a 2.4% year-over-year revenue decrease. Analysts currently hold a "Hold" consensus rating for PBH, with an average price target of $80.60.
King Luther Capital Management Corp Buys Shares of 36,347 Prestige Consumer Healthcare Inc. $PBH
King Luther Capital Management Corp has acquired a new position in Prestige Consumer Healthcare (NYSE: PBH), purchasing 36,347 shares valued at approximately $2.27 million. This investment represents about 0.07% of the company's stock. Other institutional investors have also adjusted their holdings in PBH, with the company reporting quarterly EPS of $1.14 and revenue of $283.44 million, slightly below analyst expectations.
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)’s Quarterly Revenue
Prestige Consumer Healthcare Inc. (PBH) reported a 2.4% year-over-year decline in fiscal third-quarter sales, primarily due to supply issues with its Clear Eyes brand. Despite this, sales of $283.4 million were roughly in line with company projections and slightly above Street estimates. Canaccord maintained a Buy rating on PBH but slightly reduced its price target to $86.
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)'s Quarterly Revenue
Prestige Consumer Healthcare Inc. (PBH) reported a 2.4% year-over-year decline in fiscal third-quarter sales, primarily due to supply issues with its Clear Eyes brand. Despite this, sales of $283.4 million were in line with projections and slightly above Street estimates. The company reduced its fiscal 2026 sales outlook to $1.1 billion but maintained free cash flow projections of at least $245 million, while also completing an acquisition and share repurchases.
Prestige Consumer Healthcare (PBH) SVP sells 1,000 common shares
Prestige Consumer Healthcare Inc.'s Senior VP of Operations, Jeffrey Zerillo, sold 1,000 shares of company common stock on February 11, 2026, at a price of $65.93 per share. This open-market transaction was reported in an SEC Form 4 filing. Following the sale, Mr. Zerillo directly owns 41,048 shares of Prestige Consumer common stock.
Envestnet Asset Management Inc. Has $15.48 Million Stake in Prestige Consumer Healthcare Inc. $PBH
Envestnet Asset Management Inc. has reduced its holdings in Prestige Consumer Healthcare Inc. by 7.6%, now owning 248,058 shares valued at $15.48 million. Other institutional investors have increased their stakes, bringing total institutional ownership to 99.95%. The company's recent earnings missed analyst estimates, and analysts currently rate the stock as "Hold" with an average target price of $80.60.
Insider Sell: Jeffrey Zerillo Sells 1,000 Shares of Prestige Con
Jeffrey Zerillo, Senior Vice President of Operations at Prestige Consumer Healthcare Inc's subsidiary, sold 1,000 shares of the company on February 11, 2026. Following this transaction, Zerillo now owns 41,048 shares. The stock is currently deemed fairly valued based on its GF Value, with a price-to-GF-Value ratio of 0.99.
Prestige Consumer Healthcare (NYSE:PBH) VP Sells $65,930.00 in Stock
Prestige Consumer Healthcare's VP, Jeffrey Zerillo, sold 1,000 shares of company stock worth $65,930 on February 11th, reducing his holding by 2.38%. This transaction follows previous sales in December and November. The company recently reported Q4 earnings of $1.14 per share, missing consensus estimates, and provided FY2026 EPS guidance of $4.54.
PBH's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Up
Prestige Consumer Healthcare Inc. (PBH) reported mixed results for its fiscal third quarter of 2026, with diluted EPS of $1.14 missing estimates but total revenues of $283.4 million surpassing expectations. The company's stock edged up 0.6% after the announcement. Despite beating revenue estimates, the company faced challenges with lower Eye & Ear Care category sales and narrowing operating margins, leading to a narrowed fiscal 2026 sales outlook.
